SCHEMBL1948541

SCHEMBL1948541

Cn1cnc(S(=O)(=O)N(Cc2ccc(Cl)cc2)c2ccc3c(c2)N(C(=O)OC(C)(C)C)CC3)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 3/20 0.39
FNTB P49356 3/20 0.39
PGGT1B P53609 1/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
OXTR P30559 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
DRD2 P14416 4/20 0.35
DRD4 P21917 3/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
SLC6A9 P48067 1/20 0.35
CHRM4 P08173 1/20 0.35
HTR7 P34969 1/20 0.35
NOTUM Q6P988 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1948644 0.94 FNTA (0.39) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL2641040 0.89 MEN1 (0.41) FNTAFNTBMEN1KMT2AOXTR
SCHEMBL1947912 0.88 ESR2 (0.46) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL1948520 0.86 ALDH1A1 (0.36) MEN1KMT2AALDH1A1GAADRD2
SCHEMBL1951261 0.86 DRD2 (0.38) MEN1KMT2AOXTRALDH1A1GAA
SCHEMBL1951599 0.80 DRD2 (0.40) ALDH1A1GAADRD2DRD4NOTUM
SCHEMBL1723122 0.80 FNTA (0.55) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL1949522 0.79 LMNA (0.42) MEN1KMT2AALDH1A1GAAPOLB
SCHEMBL3376298 0.78 FNTA (0.48) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL1949362 0.77 LMNA (0.45) MEN1KMT2AOXTRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438055-B1 DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS JAPAN TOBACCO INC (JP) 2018-10-24 EP disclosed
US-8426442-B2 Compounds XENTION LTD (GB) 2013-04-23 US disclosed
US-20110136860-A1 Compounds XENTION LTD. (GB) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136860-A1 Compounds NR3C2, NR5A1, NR0B2 FNTA 1682/4885FNTB 2328/4885PGGT1B 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.